This review describes the heterogeneity of peripheral glial cell populations, from the emergence of Schwann cells (SCs) in early development, to their involvement, and that of their derivatives in adult glial populations. We focus on the origin of the first glial precursors from neural crest cells (NCCs), and their ability to differentiate into several cell types during development. We also discuss the heterogeneity of embryonic glia in light of the latest data from genetic tracing and transcriptome analysis. Special attention has been paid to the biology of glial populations in adult animals, by highlighting common features of different glial cell types and molecular differences that modulate their functions. Finally, we consider the communication of glial cells with axons of neurons in normal and pathological conditions. In conclusion, the present review details how information available on glial cell types and their functions in normal and pathological conditions may be utilized in the development of novel therapeutic strategies for the treatment of patients with neurodiseases.
Summary: Neural organoids are three-dimensional stem cell-derived models widely used to study brain development and model disease. Brightfield imaging offers a non-invasive readout of their growth and morphology, and recent advances have made automated organoid segmentation from such images increasingly attainable. Yet existing tools largely leave morphological characterization, quality assessment, and comparisons between conditions to manual or ad hoc analysis. Here we present Organotchi, an open-source tool that integrates automated segmentation with longitudinal morphological analysis of neural organoids. Organotchi quantifies ten morphological features, including area, perimeter, and eccentricity, and tracks cystic structures over time, reports variability within and between batches, and flags outlier organoids and segmentation failures, supporting objective organoid characterization and enhancing downstream analysis. As a proof of concept, we apply Organotchi to disease modelling, pharmacological perturbation, and protocol optimization in neural organoids. One use case assesses drug response in breast cancer spheroids, demonstrating its use beyond its development domain.